This prediction warrants rigorous validation in future studies using CRC mouse models (e.g., with FMT or butyrate treatment), where we would expect to observe increased CD8+ T-cell infiltration and reduced PD-1 expression upon successful intervention. The gene discussed is PDCD1; the disease is colorectal carcinoma.